NRX Pharmaceuticals, Inc. (BRPA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Lumos Pharma, Inc.

NRX Pharmaceuticals, Inc.

Cumberland Pharmaceuticals, Inc.

Regulus Therapeutics, Inc.

Corbus Pharmaceuticals Holdings, Inc.

MyMD Pharmaceuticals, Inc.

Cellectar Biosciences, Inc.

Matinas BioPharma Holdings, Inc.

NLS Pharmaceutics Ltd.

AgeX Therapeutics, Inc.

Qilian International Holding Group Ltd.

Why is NRX Pharmaceuticals, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 17.40% and Operating profit at -270.48% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -16.34

Flat results in Mar 26

INTEREST(9M) At USD 0.9 MM has Grown at inf%
DEBT-EQUITY RATIO (HY) Highest at 41.83 %
OPERATING PROFIT(Q) Lowest at USD -4.58 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 21.29%, its profits have risen by 44.5%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is NRX Pharmaceuticals, Inc. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

NRX Pharmaceuticals, Inc.

21.29%

0.21

88.09%

S&P 500

22.24%

1.67

13.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

17.40%

EBIT Growth (5y)

-270.48%

EBIT to Interest (avg)

-16.34

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.11

Sales to Capital Employed (avg)

-0.05

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

44.73%

ROCE (avg)

ROE (avg)

0.23%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-4.54

EV to EBIT

-4.01

EV to EBITDA

-4.05

EV to Capital Employed

-2.77

EV to Sales

53.01

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -2,547% (YoY

NET SALES(9M)

Higher at USD 2.29 MM

NET PROFIT(9M)

Higher at USD -9.02 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 25.34 times

-11What is not working for the Company

INTEREST(9M)

At USD 0.9 MM has Grown at inf%

DEBT-EQUITY RATIO (HY)

Highest at 41.83 %

OPERATING PROFIT(Q)

Lowest at USD -4.58 MM

PRE-TAX PROFIT(Q)

Fallen at -32.89%

NET PROFIT(Q)

Fallen at -32.89%

Here's what is working for NRX Pharmaceuticals, Inc.

Net Sales

At USD 2.29 MM has Grown at inf%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Debtors Turnover Ratio

Highest at 25.34 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Net Sales

Higher at USD 2.29 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Raw Material Cost

Fallen by -2,547% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for NRX Pharmaceuticals, Inc.

Interest

At USD 0.9 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Profit

Lowest at USD -4.58 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Fallen at -32.89%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Fallen at -32.89%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at 41.83 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio